Xinghua L. Han

Lujiang Road 17
Hefei, 230001, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.

Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.

Journal: Journal for immunotherapy of cancer
Published: May 20, 2026

Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.

Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 09, 2026

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology
Published: November 14, 2025

The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell.

The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell.

Journal: International journal of biological sciences
Published: September 28, 2025

Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA.

Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA.

Journal: Genome medicine
Published: July 16, 2025

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

Journal: Cancer cell
Published: April 29, 2025

BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1⁺ macrophage-mediated immune evasion in triple-negative breast cancer.

BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1⁺ macrophage-mediated immune evasion in triple-negative breast cancer.

Journal: Oncogene
Published: March 13, 2025

Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis.

Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis.

Journal: Breast cancer research : BCR
Published: March 03, 2025

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Journal: Signal transduction and targeted therapy
Published: February 24, 2025

Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4.

Estrogen-induced FXR1 promotes endocrine resistance and bone metastasis in breast cancer via BCL2 and GPX4.

Journal: Frontiers in cell and developmental biology
Published: January 19, 2025

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.

Journal: Molecular cancer
Published: December 03, 2024

ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway.

ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway.

Journal: Hepatology communications
Published: November 29, 2024
Showing 1-12 of 52

Last Updated: 09/26/2026